Specialty pharmaceutical maker Allergan (formerly Actavis) isn't content with leading a generic life. Although formerly #3 in the global generics market behind Teva Pharmaceutical and Sandoz, Allergan has reinvented itself as a branded growth pharmaceutical. In 2016 the company sold its portfolio of more than 1,000 generic products to Teva for $40.5 billion. Allergan is now focused on expanding the number of branded drugs in its portfolio. These drugs  are principally geared at urology and women's health. In 2016 Allergan and US-based Pfizer called off their planned $160 billion merger, citing tax reasons.